EKF Diagnostics, the global point-of-care diagnostics business, will premier two novel diagnostic tests next week (November 20-23) at Medica 2013 in Düsseldorf, Germany.
EKF will introduce an updated version of Lactate Scout+, a hand-held POC analyzer for the measurement of lactate. According to company spokespersons, this third version of Lactate Scout+ features hematocrit compensation that ensures that results are highly accurate, particularly in subjects with high concentrations of hematocrit, such as elite athletes and neonates, and provides fast results (10 seconds) from the smallest sample of capillary blood (0.2 µL).
The second test EK will introduce is a new test kit for Soluble Tumor Necrosis Factor receptor 1 (sTNFr1). sTNFr1 identifies diabetic patients at high risk of End Stage Renal Disease (ESRD) up to 10 years in advance. Based on a standard ELISA, the test detects circulating levels of sTNFr1 in just a few hours. Early diagnosis of ESRD leads to improved patient outcomes and reduced healthcare costs. The ELISA kit was developed in conjunction with the Joslin Diabetes Center in Boston.
EKF CEO Julian Baines comments, “Twenty years after the onset of overt nephropathy, approximately 20% of diabetic patients will have progressed to ESRD. Our sTNFr1 assay will lead to improvements in the way patients are managed and reduce the burden on healthcare systems. We are confident that sTNFr1 will provide a step-change in the way ESRD is detected and managed, and we are in the process of identifying accredited test labs in the United States to complement our work in Europe.” Learn about glucose and lactate analyzers available from EKF.
